Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

2014 ASH Annual Meeting

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of tyrosine kinase inhibitors, monoclonal antibodies, and CAR T cells.

Leukemia

Richard M. Stone, MD

Oct

Today In Oncology

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Related Videos

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

Richard M. Stone, MD, on the SAL-SORAML Trial

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Thymic Health Associated With ICI Response

First-Line PD-1/PD-L1 Inhibitors vs BRAF Plus MEK Inhibitors in BRAF V600E-Mutated Metastatic NSCLC

Multidisciplinary Program Doubles Lung Cancer Screening Rates

New Leadership Elected to the American Society of Hematology

Lisaftoclax Regimens Effective in Plasma Cell Disorders